Recent advances in the phencyclidine model of schizophrenia

Sayed Y, 1983, Psychopharmacol Bull, 19, 283

10.1176/ajp.119.1.61

Collins VJ, 1960, Cyclohexylamines. Anesth Analg, 39, 303

10.1213/00000539-195809000-00007

10.1093/bja/31.10.433

10.1213/00000539-196601000-00007

10.1097/00005053-195907000-00006

10.1016/S0010-440X(61)80033-3

10.1001/archneurpsyc.1959.02340150095011

10.1177/070674376100600307

10.1192/bjp.106.444.912

Domino EF, 1981, PCP (Phencyclidine): Historical and Current Perspectives

10.1016/0013-4694(59)90122-1

10.1001/archpsyc.1959.03590060113013

Cohen BD, 1961, Arch Gen Psychiatry, 6, 79

10.1001/archpsyc.1988.01800310020002

10.1097/00005053-198307000-00008

10.1177/070674376701200217

10.1001/archpsyc.1976.01770120029002

Angrist B, Rotrosen J: Partial improvement in negative schizophrenic symptoms after amphetamine. Psychopharmacology (Berlin) I 982

10.3109/15563657608988151

10.1176/ajp.135.9.1081

10.1176/ajp.132.10.1076

10.1016/S0196-0644(81)80118-7

Erard R, Peele R: The PCP psychosis: prolonged intoxication or drug-precipitated functional illness? i Psychedelic Drugs 1980

Yesavage JA, 1978, J Clin Psychiatry, 44, 664

10.1007/BF00216006

Cook CE, 1983, Fed Proc, 42, 2566

10.1093/jat/7.2.106

Pearce DS, 1976, Clin Chem, 22, 1623, 10.1093/clinchem/22.10.1623

10.1016/0041-008X(76)90118-6

10.1001/jama.1975.03260180053024

10.1176/ajp.136.10.1341

Foster HM, 1986, J Clin Psychiatry, 47, 428

Rothman, 1988, J Pharmacol Exp Ther, 246, 137

Albuquerque EX, 1983, Fed Proc, 42, 2584

Schwartz RD, 1988, J Pharmacol Exp Ther, 244, 963

10.1016/0006-8993(78)90145-2

Becher CE, 1969, Clin Chem, 45, 780

10.1073/pnas.76.10.5372

Vincent JP, Lazdunski M: Interaction of phencyclidine ("angel dust") with a specific receptor in rat brain membranes. Proc NatI Acad Sci USA 1979

10.1016/0006-8993(87)91606-4

10.1111/j.1471-4159.1988.tb13260.x

10.1016/0006-8993(83)91151-4

10.1176/jnp.2.1.44

10.1016/0014-2999(88)90235-X

10.1037/e468272004-001

10.1016/0014-2999(88)90498-0

Shannon HE, 1981, J Pharmacol Exp Ther, 216, 543

Johnson KM, 1983, Fed Proc, 42, 2579

10.1016/0091-3057(85)90137-6

Fessler RG, Sturgeon RD

10.1007/BF01258633

Koek W, 1989, J Pharmacol Exp Ther, 250, 1019

Nieollon A, Duticier N: Presynaptic controls in the neostriatum: reciprocal interactions between the nigro-striatal dopaminergic neurons and the cortico-striatal glutamatergic pathway. Exp Brain Res (suppl) 1983

10.1016/0006-8993(82)90277-3

10.1016/0006-8993(89)90186-8

10.1016/0304-3940(88)90150-4

10.1016/0028-3908(83)90213-7

Schmidt WJ, Intrastriatal injection ofDL-2-amino-S phosphonovaleric acid (AP-S) induces sniffing stereotypy that is antagonized by haloperidol and clozapine. Psychopharmacology ha) 1986

10.1213/00000539-196003000-00004

10.1016/0014-2999(87)90635-2

10.3109/15563657608988153

10.1016/0091-3057(87)90136-5

10.1016/0091-3057(84)90313-7

10.1016/0091-3057(89)90345-6

Moerschbaecher JM, 1983, J Pharmacol Exp Ther, 226, 738

10.1093/schbul/13.2.261

10.1001/archpsyc.1982.04290070025006

10.1016/0022-3956(74)90064-8

10.1001/archpsyc.1972.01750200001001

10.1192/bjp.111.477.701

Schneider K, 1959, Clinical Psychopathology

Henn FA, 1982, Schizophrenia as a Brain Disease

10.1001/archpsyc.1973.01750360069010

Bleuler EP, 1908, Dementia Praecox or the Group of Schizophrenias

10.1093/schbul/11.3.409

10.1007/978-3-642-71288-3_30

10.1093/schbul/16.3.537

10.1001/archpsyc.1989.01810120087013

10.1016/0166-2236(90)90058-I

10.1001/archpsyc.1988.01800310013001

10.1093/schbul/14.2.209

10.1111/j.1471-4159.1989.tb11760.x

10.1016/0196-9781(84)90124-4

10.1016/0006-8993(87)91499-5

10.1126/science.2841762

10.1146/annurev.ps.37.020186.001451

10.1111/j.1600-0447.1974.tb09707.x

10.1093/schbul/14.2.157

10.1001/archpsyc.1989.01810110077011

10.1016/0006-3223(88)90093-5

10.1097/00002826-198910000-00006